Form 4: Natera CEO Sells Shares Under 10b5-1 Plan

Natera's CEO and President, Steven Leonard Chapman, sold 5,807 shares of common stock in early August 2025 under a pre-arranged trading plan.

Summary

• Steven Leonard Chapman, Natera, Inc.'s CEO and President, reported the sale of 5,807 shares of Natera common stock.
• The transactions occurred on August 1, 2025, which is a future date relative to the filing date of August 5, 2025.
• The sales were executed in two separate transactions: 2,810 shares at a weighted average price of $132.4264 per share (ranging from $131.8850 to $132.87) and 2,997 shares at a weighted average price of $133.3127 per share (ranging from $132.9350 to $133.80).
• These sales were conducted pursuant to a Rule 10b5-1 trading plan, which was initially adopted on December 11, 2023, and subsequently amended on December 2, 2024.
• Following these transactions, Steven Leonard Chapman beneficially owns 163,593 shares of Natera common stock.

Sentiment

Score: 5

Explanation: The sale of shares by the CEO is a routine transaction under a pre-arranged 10b5-1 plan, which typically minimizes negative sentiment associated with insider selling. However, it still represents a reduction in insider ownership.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled transaction rather than a reaction to immediate market events or new information.

Negatives

• The transaction date of August 1, 2025, is in the future relative to the filing date of August 5, 2025, which is highly unusual for a Form 4 and may indicate a clerical error or an atypical reporting schedule.
• The sale represents a reduction in direct insider ownership by the CEO and President.

Future Outlook

The filing details a pre-scheduled insider stock sale and does not provide any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or diagnostics sector.

Stakeholder Impact

• Shareholders will note the reduction in the CEO's direct ownership, though the pre-arranged nature of the sale under a 10b5-1 plan generally mitigates concerns about management's confidence in the company's future.

Key Dates

Recommendation

The filing details a pre-scheduled sale of shares by the CEO under a Rule 10b5-1 trading plan. Such transactions are generally considered routine and do not typically signal a change in the company's fundamental outlook or warrant a shift in investment strategy. The sale reduces insider ownership but is not indicative of a lack of confidence given the pre-arranged nature.

Keywords

Natera, NTRA, Steven Chapman, CEO, insider trading, Form 4, stock sale, 10b5-1 plan, biotechnology, diagnostics